Inschrijving en Covid safe ticket verplicht om deel te nemen. Meer informatie op deze pagina
“Biomanufacturing: the future starts in Belgium” : Het jaarevent van bio.be/essenscia op 21 september staat in het teken van de opportuniteiten in de Belgische bioproductie. Thomas Dermine, staatssecretaris voor Relance en Strategische Investeringen, belast met Wetenschapsbeleid, is de centrale gast.
Er waait een nieuwe wind in de Belgische biotechsector. De biotechbedrijven evolueren steeds meer van ‘invented in Belgium’ naar ‘made in Belgium’. Tijdens dit evenement nemen we de volgende vragen onder de loep: Welke opportuniteiten brengt het relanceplan met zich mee? Hoe verhoudt de productiecapaciteit van Belgische biotechbedrijven zich ten opzichte van de internationale concurrentie? Welke kansen liggen er op het vlak van digitalisering en duurzaamheid? En hoe kan België uitgroeien tot een referentiepunt voor expertise in ‘factories of the future’?
Het jaarevent heeft plaats in BluePoint Brussel in het Engels en wordt georganiseerd volgens de coronamaatregelen.
Programma
- 13:15 : Welcome & Registration
- 14:00 : Introduction
Tineke Van hooland, Deputy Secretary General bio.be - Keynote speech
Thomas Dermine, State Secretary for Economic Recovery and Strategic investments in charge of Scientific Policy - Panel debate
Eva Leclercq, Digital Transformation – Univercells
Benoit van den Hove, Head of Listing Belgium and Luxembourg – Euronext
Julien Moindrot, Site Head – Sanofi
Hendrik Waegeman, Head of Business Operations – Bio Base Europe Pilot Plant
Moderated by Frédéric Druck, Secretary General bio.be/essenscia, with - Company testimonial videos from Johnson & Johnson, GSK and Univercells
- Conclusion
Geoffrey Pot, President board bio.be - 15:45 : Networking reception
Inschrijving en Covid safe ticket verplicht om deel te nemen. Meer informatie op deze pagina
 |
Thomas Dermine, is a French-speaking Belgian economist and politician who is a member of the Socialist Party.
On 1 October 2020, he was appointed State Secretary for Economic Recovery and Strategic Investment with responsibility for Science Policy, deputy to the Minister for the Economy and Labour in Alexander De Croo’s federal government. Within the federal government, he is responsible for steering the coordination of the Belgian Recovery Plan and ensuring close cooperation between the European Commission and Belgium. In parallel with this mission, Thomas also supervises the Federal Science Policy, including 10 federal scientific establishments and a multitude of competences ranging from Belgian aerospace policy to the management of federal museums and federal research policy. |
 |
Eva Leclercq is digital transformation manager at Univercells and drives digital transformation projects across the 4 affiliates of the Belgian group. After graduating in business engineering from Université de Liège and Université Catholique de Louvain, she joined Accenture as a consultant in digital analytics, and managed innovative projects across R&D, quality, commercial, etc. for several big pharmaceutical groups. |
 |
Julien Moindrot holds a master’s degree in engineering from the Ecole des Arts et Métiers de Paris (ENSAM – Paris, France) and is certified in Environmental Technologies (University of Trondheim, Norway). He has more than 20 years of experience in the pharmaceutical and biotech environment, holding several roles in Project management, Engineering, Business Excellence and Transformation.
Julien has more than 10 years of experience within Sanofi, where he started as Head of Business Excellence & Engineering and evolved to Head of Strategy and Industrial Performance in Geel. In 2016, Julien was appointed Global Transformation Leader, responsible for the operational and performance transformation of 7 sites of the Biologics platform. Since November 2020 Julien leads the bio-manufacturing site of Sanofi in Geel (> 800 employees) as Site Head. |
 |
Geoffrey Pot studied Pharmacy / Industrial Pharmacy and has more than 15 years of experience in the Biotech environment. He followed an International Management Degree at the Vlerick Business School, and has a natural passion for innovation and digital. He has been holding several roles of increasing responsibility in Quality, Operational Excellence, Project management, Manufacturing, and Innovation. As of today, Geoffrey is a Vice President, and is responsible for the Lessines manufacturing plant (>1200 employees) where they produce lifesaving medication. He is also the President of Belgian Biotech Industries (bio.be/essenscia) and chairman in multiple international conferences. |
 |
Benoît is Head of Listing of Euronext Brussels and Luxembourg. He joined Euronext in 2018 after having spent 17 years in a leading Benelux bank where he held different roles in the financial and capital markets and 2 years in a law firm. Benoit holds a Master’s Degree in Law (KULeuven) and an executive Masters in Business Administration (Louvain School of Management |
 |
Hendrik Waegeman obtained a master degree in biochemical engineering at Ghent University (2007) and holds a PhD in Applied Biological Sciences-Chemical Engineering (2011), also obtained at Ghent University. During his doctoral research he metabolically engineered Esherichia coli to improve recombinant protein production. During his post-doctoral research, Hendrik Waegeman was involved in a number of projects that focused on the fermentative production of specialty carbohydrates. He is also a co-founder of the company Inbiose NV, founded in 2013, which develops fermentatively produced specialty carbohydrates such as human milk oligoscaccharides. In 2012 he was guest lecturer at the University of Incheon, South-Korea where he lectured a course on Metabolic Engineering and Modelling of Micro-organisms. Since 2012, he has a position at Bio Base Europe Pilot Plant, a multi-purpose pilot facility in the Port of Ghent in Belgium where he has worked as Head of Business Development and is now Head of Business Operations.
Hendrik is also board director of Inbisoe NV, Bio.be (the cluster of Belgian biotech companies) and Biobased Industries Consortium (BIC, the private partner in the joint undertaking Horizon2020-BBI and the upcoming joint undertaking CBE (Circular Bio-based Europe). |
